AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025
Park-Simon TW., Müller V., Albert US., Banys-Paluchowski M., Bartsch R., Bauerfeind I.
Narrative Review, published in Breast Care (Basel) (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Breast Care (Basel) (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40236659
- PMCID
- PMC11996201
- DOI
- 10.1159/000545019
- Citations
- 9
Abstract (original English)
The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2025 update of the evidence-based recommendations for the diagnosis and treatment of patients with early breast cancer.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.